MSH’s Dr. Rabia Kahveci Appointed as Vice President and President-Elect of Health Technology Assessment International’s Board of Directors

 Dr. Rabia Kahveci presents at a Ukraine's first national national health technology assessment forum.

MSH congratulates Dr. Rabia Kahveci for her appointment as board vice president and president-elect of Health Technology Assessment international (HTAi), a nonprofit organization dedicated to fostering health technology assessments worldwide. The two-year appointment will lead to Dr. Kahveci assuming the presidency of the organization in 2023. Dr. Kahveci is MSH’s senior technical advisor for pharmaceutical policy and governance and has also served as a board director with HTAi from 2014 to 2020 and as chair of the HTAi Developing Countries Interest Group and co-chair of the Medical Devices Interest Group. In addition, she served as the Chair of the Eurasian Health Technology Assessment (HTA) Initiative. 

A medical doctor with a degree in HTA, Dr. Kahveci has authored more than 150 peer-reviewed journal articles and eight books and has delivered more than 300 scientific presentations at international meetings on HTA. Prior to joining MSH, Dr. Kahveci was the director of the Health Technology Assessment Unit at Ankara Numune Training and Research Hospital in Ankara, Turkey, and a professor of family medicine at the same hospital. She contributed to numerous national and international projects around HTA, including the European Network for Health Technology Assessment (EUnetHTA) and Adopting Hospital-Based Health Technology Assessment (AdHopHTA). In 2017, Dr. Kahveci served as the national clinical quality coordinator of the Turkish Ministry of Health, where she coordinated all activities involving HTA, clinical guidelines, and quality.

Dr. Kahveci’s previous roles include serving on the Pharmaceuticals Reimbursement Committee of the Turkish Social Security Institution during the transition to universal health coverage, and she co-authored the reimbursement guidelines. She worked at the Turkish Medicines Agency on pricing and reimbursement of pharmaceuticals and led the agency’s HTA work.

More information about HTAi is available here.